secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2026-05-15T10:02:44+00:00
Accession:  0001193125-26-225055
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma reports Q1 revenue $22.7M, neffy net product revenue $17.5M
----------------------------------------------------------------------

- Net loss $60.6M ($0.61/share); cash $201M; expects to fund to cash-flow break-even.
- CVS Caremark formulary proposal in final stages; target July 1, 2026; gross-to-net target ~50%.
- Sales force expanded to 148 reps; SG&A $72.2M includes DTC marketing investment.
- Health Canada approved neffy on April 15; EU 1 mg dose approved for children 4+ years.
- Phase 2b CSU trial interim population fully enrolled; data expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/0001193125-26-225055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/spry-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-225055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer